Related Experiment Video
Updated: Jul 19, 2026
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Multiple rather than specific autoantibodies were identified in irritable bowel syndrome with HuProt™ proteome
Wenjuan Fan1,2, Xiucai Fang1, Chaojun Hu3
1Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
This study investigated serum autoantibodies as biomarkers for irritable bowel syndrome (IBS). While a combination of autoantibodies showed potential in differentiating IBS patients from healthy controls, no single autoantibody proved effective as a reliable biomarker.
Area of Science:
- Gastroenterology
- Immunology
- Biomarker Discovery
Background:
- Irritable bowel syndrome (IBS) pathophysiology may involve immune activation and autoantibodies.
- Identifying reliable serum biomarkers for IBS remains a clinical challenge.
Purpose of the Study:
- To identify potential serum autoantibody biomarkers for irritable bowel syndrome (IBS) using HuProt™ microarray technology.
- To evaluate the diagnostic potential of identified autoantibodies in differentiating IBS patients from healthy and disease controls.
Main Methods:
- HuProt™ microarray profiling of sera from IBS patients and controls (healthy and disease).
- Validation of differentially expressed autoantibodies in a larger cohort using IBS-focused microarrays.
- Generation of decision tree models and ELISA verification of candidate biomarkers.
- Correlation analysis of autoantibodies with IBS symptoms.
Main Results:
- Significant differences in autoantibody profiles (IgG and IgA) were observed between IBS patients and controls.
- A panel of 14 IgG and IgA autoantibodies showed higher positive rates in IBS patients compared to healthy controls.
- A combination of five IgG and seven IgA autoantibodies demonstrated moderate sensitivity (40%-46.7%) and high specificity (79.4%-86.3%) in differentiating IBS from healthy controls.
- Specific autoantibodies like ELAVL4 (IgG) and PIGP (IgA) showed elevated levels in IBS patients.
Conclusions:
- A combination of autoantibodies can help differentiate irritable bowel syndrome (IBS) patients from healthy individuals.
- No single autoantibody identified in this study is sufficient to serve as a definitive serum biomarker for IBS diagnosis.
More Related Videos
10:16Generation of Two-color Antigen Microarrays for the Simultaneous Detection of IgG and IgM Autoantibodies
Published on: September 15, 2016
10:37Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:23Irritable Bowel Syndrome